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Walking performance is positively
correlated to calf muscle fiber size in peripheral
artery disease subjects, but fibers show aberrant
mitophagy: an observational study
Sarah H. White1 , Mary M. McDermott2,3*, Robert L. Sufit4, Kate Kosmac1, Alex W. Bugg1,
Marta Gonzalez‑Freire5, Luigi Ferrucci5, Lu Tian6, Lihui Zhao3, Ying Gao3, Melina R. Kibbe7,8, Michael H. Criqui9,
Christiaan Leeuwenburgh10 and Charlotte A. Peterson1*

Abstract
Background: Patients with lower extremity peripheral artery disease (PAD) have decreased mobility, which is not
fully explained by impaired blood supply to the lower limb. Additionally, reports are conflicted regarding fiber type
distribution patterns in PAD, but agree that skeletal muscle mitochondrial respiration is impaired.
Methods: To test the hypothesis that reduced muscle fiber oxidative activity and type I distribution are negatively
associated with walking performance in PAD, calf muscle biopsies from non-PAD (n = 7) and PAD participants
(n = 26) were analyzed immunohistochemically for fiber type and size, oxidative activity, markers of autophagy, and
capillary density. Data were analyzed using analysis of covariance.
Results: There was a wide range in fiber type distribution among subjects with PAD (9–81 % type I fibers) that did
not correlate with walking performance. However, mean type I fiber size correlated with 4-min normal- and fastestpaced walk velocity (r = 0.4940, P = 0.010 and r = 0.4944, P = 0.010, respectively). Although intensity of succinate
dehydrogenase activity staining was consistent with fiber type, up to 17 % of oxidative fibers were devoid of mito‑
chondria in their cores, and the core showed accumulation of the autophagic marker, LC3, which did not completely
co-localize with LAMP2, a lysosome marker.
Conclusions: Calf muscle type I fiber size positively correlates with walking performance in PAD. Accumulation
of LC3 and a lack of co-localization of LC3 with LAMP2 in the area depleted of mitochondria in PAD fibers suggests
impaired clearance of damaged mitochondria, which may contribute to reduced muscle oxidative capacity. Further
study is needed to determine whether defective mitophagy is associated with decline in function over time, and
whether interventions aimed at preserving mitochondrial function and improving autophagy can improve walking
performance in PAD.
Keywords: Mitochondria, Mitophagy, Fiber type, Calf muscle, Peripheral artery disease
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Background
Patients with lower extremity peripheral artery disease
(PAD), caused by atherosclerosis in the lower extremities, have faster functional decline and higher rates of
mobility loss compared to people without PAD [1–7]. As
therapeutic advances have not kept pace with the growing burden of disability from this chronic disease [8], new
approaches are urgently needed to prevent disability in
patients with PAD.
Patients with PAD experience ischemia of lower limb
skeletal muscle during walking activity, when metabolic
demands exceed oxygen supply, followed by reperfusion
during rest. Ischemia has been demonstrated to damage
skeletal muscle fibers and impair mitochondrial activity, and reperfusion exacerbates this damage [9–13]. As
a result, small studies of PAD participants show quantitative mitochondrial dysfunction in gastrocnemius
muscle, with reduced ATP production [11, 14]. Low
mitochondrial activity, measured either by respirometry
from muscle biopsy specimens or using magnetic resonance spectroscopy, is associated with poorer treadmill
walking in people with PAD [9, 14]. Moreover, while
mitochondria-specific autophagy, known as mitophagy,
has not been directly explored in PAD, electron microscopy of gastrocnemius biopsies in patients with PAD
shows pathologic changes in mitochondria [15]. Further,
research has shown that gastrocnemius mitochondrial
content may predict mortality rate in PAD [16]. While
bypass surgery improves walking performance in PAD
patients [17], it is associated with a higher degree of
morbidity and mortality, and patients may later require
additional procedures with a greater risk of limb loss [18].
Therefore, alternative strategies, perhaps targeting mitochondrial health, may be advantageous targets of future
therapies for PAD patients.
Human skeletal muscle is characterized by three main
fiber types, which vary in fatigue resistance and oxidative potential. Type I, slow-twitch fibers have the greatest
mitochondrial density and, therefore, greatest oxidative
metabolism, resulting in high resistance to fatigue [19].
Types IIa and IIx are fast-twitch fibers, with IIa having intermediate oxidative activity and fatigability and
IIx relying primarily on glycolytic, anaerobic metabolism, fatiguing the most quickly [19]. Muscle fiber type
composition, which is normally closely associated with
mitochondrial oxidative capacity, is altered in muscle
from PAD patients, but reports are contradictory. In
patients with PAD, a decrease in type I fibers, an increase
in type IIx fibers, and smaller cross-sectional area of
type I and IIa fibers in the gastrocnemius muscle have
been reported [20]. On the other hand, several studies
show that PAD results in an increase in the muscle area
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occupied by oxidative type I fibers [21–23] (reviewed in
[24]). Whether specific fiber type alterations are associated with more severe mobility impairment in PAD
patients is unknown.
The considerable variability in reports on fiber type
alterations in PAD led us to hypothesize that fiber type
composition in the gastrocnemius muscle would directly
relate to walking performance in PAD. Additional features that may relate to functional performance were also
evaluated, including capillary density and mitochondrial
content. These analyses suggest potential new targets in
muscle for the development of effective interventions to
improve muscle function and mobility in PAD patients.

Methods
Participant identification, recruitment methods,
and ethical approval

PAD (n = 26) and non-PAD (n = 7) participants were
identified from among participants in five studies at
Northwestern University Feinberg School of Medicine.
Two studies were observational cohort studies [the
walking and leg circulation study iii (WALCS III) and
Biomarker Risk Assessment in Vulnerable Outpatients
(BRAVO)] [25–27] and three studies were randomized
trials [Group Oriented Arterial Leg Study (GOALS), Progenitor Cells to Improve Leg Functioning in PAD (PROPEL)] [28–30], and Resveratrol To Improve Outcomes
in Older People with PAD (RESTORE). For the observational studies, participants from WALCS III and BRAVO
were recruited from among consecutively identified PAD
patients at Chicago-area medical centers who were evaluated in vascular surgery, cardiology, general medicine,
endocrinology, and geriatric clinics [25–27]. Non-PAD
participants were identified either among consecutive
men and women age 65 and older without risk factors for
PAD or cardiovascular disease in a large general internal
medicine practice at Northwestern who were screened
with the ankle brachial index (ABI) and found to have an
ABI of 0.90 to 1.30 [25] or from potential study participants for the randomized trials who were found to have a
normal ABI at the screening/baseline study visit [28–30].
Inclusion and Exclusion Criteria

All PAD participants in these analyses had a baseline
ABI value of <0.90. All non-PAD participants included in
these analyses had a baseline ABI of 0.90 to 1.30.
Exclusion criteria have been reported [25–30] and consisted of severe functional limitation, characterized by
inability to walk without a walker or wheelchair, significant cognitive impairment, terminal illness, recent major
operation or recent major cardiovascular event and lack
of willingness to return for the required study visits.
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Comorbidities

Muscle biopsies

Presence of comorbid diseases and smoking history were
obtained by administering questionnaires in a standardized fashion.

A single investigator (RLS) collected all muscle biopsies from the medial head of the gastrocnemius muscle,
at the point that was approximately 67 % of the distance
between the medial malleolus and the medial aspect of
the proximal tibia. Anesthesia was achieved with subcutaneous lidocaine. Subcutaneous and adipose tissue were
dissected until muscle was identified. Approximately
100 mg of muscle tissue was mounted in trigacanth gum
on cork and immediately frozen in liquid-nitrogen cooled
isopentane to be processed for immunohistochemical
analysis. The fascia was closed with absorbable suture,
the wound was closed with subcuticular sutures, and the
skin was closed with steri-strips.

Medications

Participants were asked to bring their medication bottles
or a complete list of their medications to their baseline
study visit. Names of each medication were recorded. A
study investigator (MMM) reviewed each medication
named and indicated whether each medication was a statin or not.
Intermittent claudication

The presence and characteristics of exertional leg symptoms were assessed using the San Diego claudication
questionnaire [31]. Participants with exertional calf pain
that did not begin at rest and that resolved within 10 min
of rest were classified with intermittent claudication [31].
Ankle brachial index

The ankle brachial index (ABI) was measured with a
handheld Doppler probe (Nicolet Vascular Pocket Dop
II, Golden, CO) to measure systolic blood pressures after
the participant rested supine for 5 min. Pressures were
measured in the following order, and then repeated in
reverse order: right brachial, dorsalis pedis, and posterior
tibial arteries; left dorsalis pedis, posterior tibial, and brachial arteries. The ABI was calculated by dividing average
pressures in each leg by the average of the four brachial
pressures [32, 33].
Six‑min walk

Following standardized instructions to complete as many
laps as possible, participants walked back and forth over
a 100-foot hallway for 6 min [1, 2, 5, 34]. Participants
were instructed to walk continuously with the goal of
covering as much ground as possible within the 6 min.
Participants were allowed to stop and rest if needed. A
research assistant walked with and slightly behind the
participant, so that the research assistant did not pace the
participant. Standardized words of encouragement were
given at 1-min intervals, for example, “One minute has
passed. You’re doing well; keep up the good work.” The
distance covered after 6 min and the distance at onset of
leg symptoms were recorded.
Four‑meter walks

Four-meter walks were performed at “normal” and “fast”
pace to measure walking velocity, based on previous
studies [35, 36]. Each walk was performed twice and the
faster walk in each pair was used.

Histochemistry/Immunohistochemistry

Seven-micrometer sections of the gastrocnemius muscle
were cut in a cryostat and allowed to dry at room temperature for 1 h. Slides were stored at −20 °C until processed as described below:
For fiber type determination (n = 26 PAD, n = 7 nonPAD), unfixed consecutive sections were incubated overnight at 4 °C with anti-laminin (#L9393; Sigma-Aldrich,
St. Louis, MO, USA) and isoform-specific myosin heavy
chain (MyHC) antibodies: MyHC type I (BA.D5; IgG2b),
IIa (SC.71; IgG1) and IIx (6H1; IgM), all from Developmental Studies Hybridoma Bank (DSHB; Iowa City, IA,
USA). The next day, slides were incubated with anti-rabbit IgG H+L AMCA (#C1-1000; Vector Laboratories,
Inc., Burlingame, CA, USA) and immunoglobulin-specific secondary antibodies: goat anti-mouse IgG2b AF647
(#A21242), goat anti-mouse IgG1 AF488 (#A21121), and
goat anti-mouse IgM AF555 (#A21426), all from Invitrogen (Grand Island, NT, USA), for 1 h. Slides were
post-fixed in methanol for 5 min and then mounted
(#H-1000; Vector Laboratories). The entire cross-section
of approximately 1000 fibers (range 600–1600) per subject was analyzed for minimum feret diameter and fiber
type. Minimum feret diameter was determined using an
interactive automated analysis program in ZEN 2 (blue
edition, v2.0, Zeiss, Oberkochen, Germany). The program calculated minimum fiber feret diameter based on
the laminin staining, which outlines fibers. Each fiber
was then assigned to either type I or type II based on the
intensity of staining within the Cy5 (type I) or FITC and
TRITC filters (type IIa and type IIx, respectively).
For lectin staining, to quantify capillary density, slides
were blocked for 1 h in normal horse serum (#S-2012;
Vector Laboratories), incubated in TRITC-labeled lectin (#L4889; Sigma-Aldrich) for 90 min at room temperature, and then mounted with fluorescent mounting
media (Vectashield, #H-1000; Vector Laboratories). The
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lectin system from Ulex europaeus has been validated as
an accurate vascular endothelial marker in human skeletal muscle [37, 38]. The lectin+ capillaries were counted
and expressed per fiber. Due to the orientation and quality of the biopsy, quantification could only be performed
on n = 18 PAD subjects. Approximately 600 fibers (range
400–750) per subject were in cross section to be accurately counted for lectin + staining.
For Oil Red O (ORO) staining, ORO stock [700 mg
ORO (#O0625; Sigma-Aldrich) and 100 mL 60 % Triethyl
phosphate (#538728; Sigma-Aldrich)] was filtered using
Whatman® #1 filter paper then diluted 3:2 with double
distilled water (ddH2O) to make the ORO working solution. Slides were fixed in 4 % paraformaldehyde for 3 min
at room temperature then rinsed in ddH2O. Slides were
then incubated in working ORO solution for 2 h, rinsed
in ddH2O, and mounted with mounting media (#H-5501;
Vector Laboratories).
For succinate dehydrogenase (SDH) activity staining,
slides were incubated in 0.75 mM nitrotetrazolium blue
(#N6876; Sigma-Aldrich), 125 mM succinic acid disodium (#224731; Sigma-Aldrich), and 75 mM PBS, pH 7.4,
for 1 h at 37 °C. Following a series of acetone rinses, slides
were mounted. Fibers that stained strongly with SDH
(++) were counted as type I fibers, fibers that stained
intermediate (+) were type IIa fibers, and those that
did not stain for SDH (−) were type IIa/x hybrids. Cavities were evident in type I and IIa fibers, but not in IIa/x
hybrids because of the lack of SDH staining in the latter.
Fibers containing distinct cavities in SDH staining greater
than 5 % of the fiber area were quantified and expressed
as a percentage of total fibers. Due to the orientation and
quality of the biopsy, quantification could only be performed on n = 18 PAD subjects. Approximately 1000 fibers (range 750–1300) were analyzed per subject.
For staining of mitochondrial complex I, subunit 20
and complex IV, subunit 1 (COX-1), slides were fixed in
4 % paraformaldehyde for 10 min, washed with TBST
(1 % Tween-20), then blocked for 1 h in TBST with 1 %
normal goat serum. Next, slides were incubated overnight at 4 °C in anti-NDUFB8 (complex I-20; #ab110242;
Abcam, Cambridge, MA) and anti-MTCO1 (COX-1;
#ab14705; Abcam) antibodies in TBST with 1 % normal
goat serum. Following TBST washes, slides were incubated in biotin goat anti-mouse IgG1 (#115-065-205;
Jackson Immuno Research, West Grove, PA, USA) and
anti-mouse IgG2a AF488 (#A21121; Invitrogen) secondary antibodies in TBST with 1 % normal goat serum for
1 h. Slides were reacted with streptavidin-horseradish
peroxidase included with the TSA kit (#T20935; Invitrogen), incubated in TSA AF594 (#T20950; Invitrogen)
in amplification diluents for 15 min, then mounted (#H1000; Vector Laboratories).
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For staining of mitochondrial COX-1 and microtubule-associated protein light chain 3 (LC3), slides were
fixed in 4 % paraformaldehyde for 10 min, washed with
TBST (1 % Tween-20), then blocked for 1 h in TBST
with 5 % normal goat serum. Slides were incubated overnight at 4 °C in anti-MTCO1 (cox-1; #ab14705; Abcam)
and anti-LC3B (#NN100-2220; Novus Biologicals, Littleton, CO, USA) antibodies in TBST with 5 % normal
goat serum. Following TBST washes, slides were incubated for 1 h in biotin goat anti-rabbit IgG (#111-065003; Jackson Immuno Research) and anti-mouse IgG2a
AF488 (#A21121; Invitrogen) secondary antibodies in
TBST with 5 % normal goat serum. Lastly, slides were
incubated in streptavidin AF594 (#S32356; Thermo Scientific, Waltham, MA, USA) for 15 min, then mounted
(#H-1000; Vector Laboratories).
For staining of LC3 and lysosome associated membrane protein 2 (LAMP2), slides were fixed in ice-cold
acetone for 10 min, washed with TBST (1× TBS with
1 % Tween-20), blocked for 1 h in TBST with 5 % normal goat serum, then incubated overnight at 4 °C in
anti-LC3B (#NN100-2220; Novus Biologicals) and antiLAMP2 (#ab25631; Abcam) antibodies in TBST (0.5 %
Tween-20) with 5 % normal goat serum. Following TBST
(1 % Tween-20) washes, slides were incubated for 1 h
in biotin goat anti-rabbit IgG (#111-065-003; Jackson
Immuno Research) in TBST (0.5 % Tween-20) with 5 %
normal goat serum, then washed in TBST (1 % Tween20). Next, slides were incubated for 2 h in streptavidin
AF594 (#S32356; Thermo Scientific) and anti-mouse
IgG2a AF488 (#A21121; Invitrogen) in TBS with 5 %
normal goat serum. Slides were then washed in TBS and
mounted (#H-1000; Vector Laboratories).
Image acquisition and analysis

Images were captured at either ×10 or ×20 magnification at room temperature with a Zeiss upright microscope (AxioImager M1; Zeiss, Oberkochen, Germany)
and analysis carried out using the Zeiss ZEN 2 software
(blue edition, v2.0). To capture the entire muscle crosssection (200–400 fibers/subject), the tiles feature within
Zen was utilized. Images of COX-1 and LC3 co-staining
were also captured at ×60 magnification at room temperature with a Nikon AIR+ confocal imaging system
and analyzed with NIS-Elements C Software (Nikon
Instruments, Inc., Melville, NY, USA). Investigators were
blinded to sample subject group for all analyses.
Real‑time quantitative PCR

RNA was extracted from PAD muscle biopsies using the
RNeasy Mini Kit (Cat. No. 74104, Qiagen, Valencia, CA,
USA). RNA quality and integrity were assessed using
the Agilent 2100 Bioanalyzer. Because of low starting
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quantities, RNA of sufficient quality was obtained from
18 subjects. Reverse transcription was performed using
the Superscript® VILO™ cDNA Synthesis Kit (Cat. No.
11754050, Life Technologies, Carlsbad, CA, USA). Quantitative real-time PCR was performed using SYBR Select
Master Mix (Cat. No. 4472903, Life Technologies) and
gene expression was normalized to the geometric mean
of three housekeeping genes: β2 microglobulin, phosphoglycerate kinase, and 18S RNA. Primer pairs are presented in Additional file 1: Table S1.
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Table 1 Characteristics of non-PAD and PAD participants
Continuous variable

Non-PAD
(n = 7)

Age (year), mean (SD)

69.71 (4.99) 66.81 (10.20) 0.474

Ankle brachial index, mean (SD)

1.13 (0.10)

Body mass index (kg/m2)a, mean
(SD)

25.15 (2.51) 28.41 (4.75)

0.257

Male sex, n

4

15

1.000

African Americans, n

1

11

0.223

Current smoker , n

0

14

0.224

Anginaa, n

0

2

1.000

Myocardial infarctiona, n

0

2

1.000

Heart failurea, n

0

0

1.000

Strokea, n

0

2

1.000

Pulmonary diseasea, n

0

5

1.000

Statistical analyses

Results
Study participant characteristics

The demographic data and clinical characteristics of PAD
and non-PAD subjects are shown in Table 1.
Fiber size, but not fiber type distribution, relates
to walking performance in subjects with PAD

Quantifying the relative abundance of type I, IIa and IIx
fibers showed that PAD participants exhibited trends
toward greater mean frequency of hybrid type IIa/x
fibers (P = 0.058) and reduced frequency of IIa fibers
(P = 0.088), but had a similar mean frequency of type I
fibers compared to non-PAD participants (Fig. 1A). Fibers expressing exclusively IIx MyHC were not detected.
Non-PAD subjects exhibited a relatively even fiber type
distribution (approximately 50 % type I and 50 % type II
fibers; representative image, Fig. 1B), typical of healthy
muscle, whereas PAD subjects demonstrated a wide
heterogeneity of fiber type distributions. Representative
images from PAD subjects with a higher percentage of

0.63 (0.14)

P value

<0.0001

Categorical variable

a

Differences in clinical and muscle characteristics
between PAD and non-PAD participants were compared using Fisher’s exact testing for categorical variables and t-testing for continuous variables. Simple
correlation coefficients between muscle fiber characteristics and functional performance measured by normal and fast paced 4-m walk velocity as well as six-min
walking distance were estimated and the significance
levels of nonzero correlations were obtained among
PAD participants. The multiple linear regression analysis was performed to examine the association of the
type I fiber size (quantified by the minimum feret diameter) and the proportion of type I fibers with functional
performance. Furthermore, the interactions between
the proportion and size of type I fiber are also tested in
the multiple regression analysis. Associations were considered significant at P ≤ 0.05 based on a two-sided test
and trends declared at P ≤ 0.10. All analyses were performed using SAS (Version 9.4, SAS Institute Inc., Cary,
NC).

PAD
(n = 26)

a
b

Cancera, n

2

3

0.068

Diabetesa, n

0

9

0.532

Intermittent claudicationa, n

0

5

1.000

Statin useb, n

2

15

1.000

Based on n = 3 non-PAD

Based on n = 4 non-PAD

type I fibers (Fig. 1C), an even distribution of type I and
type II fibers (Fig. 1D), and a higher percentage of type
II fibers (Fig. 1E) illustrate the variability. All individual
subject fiber type distributions are shown in Fig. 1F and
the relative distribution is shown in Additional file 2: Figure S1. Type I fiber frequency in individuals with PAD
ranged from 9 to 81 % (19 to 60 % in non-PAD), type IIa
abundance ranged from 8 to 72 % (20 to 65 % in nonPAD), and type IIa/x fibers ranged from 5 to 56 % (5 to
40 % in non-PAD).
We determined if fiber type frequency was associated
with walking performance in PAD subjects, measured
with 6-min walk distance, and normal- and fastestpaced 4-min walk velocities. Although the proportion
of slow-twitch, type I fibers alone did not correlate with
performance, type I fiber size, quantified by the minimum feret diameter, was strongly correlated to both
normal- and fastest-paced 4-min walk velocity (normalpaced r = 0.4940, P = 0.010; fastest-paced r = 0.4944,
P = 0.010, Table 2, Additional file 3: Figure S3A, B). The
overall average minimum feret diameter was also positively correlated to both normal- and fastest paced 4-min
walk velocity (r = 0.4804, P = 0.013 and r = 0.4137,
P = 0.036, respectively, Additional file 3: Figure S3C, D).
There was no correlation between fiber type or size and
6-min walk performance (Table 2). Further, there was a
positive interaction effect between the type I fiber percentage and type I fiber size on the normal-paced 4-min
walk velocity (P = 0.038).
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Fig. 1 Fiber type analysis of gastrocnemius muscle sections using isoform-specific myosin heavy chain (MyHC) immunohistochemistry. A Quanti‑
fication (mean ± SEM) of type I (pink), IIa (green), and IIa/x (yellow/orange) muscle fibers, shown in representative images, of non-PAD (B; n = 7) and
PAD (C–E; n = 26) participants. C–E) Representative images of PAD subjects with primarily type I fibers, 50 % type I and 50 % Type II, and primarily
type II fibers, respectively; F individual variation in fiber type distribution between non-PAD and PAD subjects (approximately 1000 fibers analyzed
per subject). Scale bar = 100 µm

Maintenance of capillary density in PAD

Consistent with previous reports [20, 24], there was a
trend for PAD subjects to have a greater number of capillaries/fiber than non-PAD (1.15 ± 0.28 vs. 1.72 ± 0.13

for non-PAD and PAD subjects, respectively; P = 0.082;
Additional file 4: Figure S4, representative images shown
in A and B, quantified in C). However, capillary density
did not correlate to fiber type (r = −0.1023 P = 0.642),

White et al. J Transl Med (2016) 14:284
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Table 2 Correlations of functional measures with muscle characteristics in PAD patients (n = 26)
Pearson correlation coefficients
(Prob > |r| under H0: Rho = 0, number of observations)

% Type I

6-min walk distance (m)

4-min walking velocity, normalpaced (m/s)

4-min walking velocity,
fastest-paced (m/s)

r value

r value

r value

P value

P value

P value

0.0067

0.975

0.1422

0.488

0.0785

0.703

−0.0539

0.798

0.314

0.829

0.0210

0.919

−0.2433

0.231

0.0456

−0.2054

Min. feret, Type I

0.3175

0.122

0.4940

0.010

0.4944

0.010

Min. feret, Type II

0.2676

0.196

0.4317

0.028

0.3713

0.062

Min. feret, average

0.3121

0.129

0.4804

0.013

0.4137

0.036

−0.0208

0.925

−0.0783

% Type IIa
% Type IIa/IIx

a

Lectin/fiber

% Fibers with cavities in SDHa
PGC1α mRNAa

0.0537

0.813

−0.1991

0.460

0.4426

0.086

0.1435

0.485

0.723

0.0993

0.714

−0.1025

0.686

0.0832

0.743

0.1580

0.531

0.0750

0.768

0.310

0.0431

0.871

−0.2675

0.283

CTRC1 mRNAa

−0.2533

HIF1α mRNAa

0.2072

0.409

−0.2480

0.321

−0.1937

0.441

CREB mRNAa

Italicized text indicates significance (P < 0.05)
a

−0.2346

0.349

−0.2495

0.318

n = 18

fiber minimum feret diameter (r = 0.1396, P = 0.525),
nor to function (Table 2).
Mitochondrial oxidative activity is impaired in PAD

Muscle sections were stained for succinate dehydrogenase (SDH) activity (Fig. 2A) to evaluate mitochondrial oxidative capacity that was then compared to fiber
type (Fig. 2B) on serial sections. As expected, fibers that
stained strongly for SDH activity (++) were type I slowtwitch fibers, fibers that stained intermediate for SDH
(+) were type IIa fibers, and fibers with lowest SDH
staining (−) were type IIa/x hybrids.
SDH activity staining indicates the presence of both
intermyofibrillar and subsarcolemmal mitochondrial
activity; PAD participants showed a loss of intermyofibrillar SDH activity in the center of up to 17 % of their
muscle fibers (4.61 ± 4.76 %, mean ± SD; Fig. 2A). These
cavities were also devoid of cytochrome c oxidase (complex IV; COX) activity (Fig. 2C), but were not centrally
necrotic, as evidenced by the presence of MyHC staining
in the center of the fibers (Fig. 2B). Additionally, the fibers showed no accumulation of ectopic lipid in the center
(ORO staining; Additional file 5: Figure S5). The percentage of fibers with absence of SDH activity in the center
(cavities) was positively correlated with type I fiber frequency (r = 0.6499; P = 0.006; Fig. 2D). Immunohistochemical analysis showed that in PAD subjects, proteins
comprising complexes I and IV (COX-1) of the electron
transport system were undetectable in the center of fibers that lacked SDH activity (Fig. 3, right column), indicating that loss of SDH activity is due to the absence of

intermyofibrillar mitochondria. The absent intermyofibrillar mitochondria were not evident in non-PAD muscle samples (Fig. 3, left column).
We analyzed PAD gastrocnemius muscle homogenate
for mRNA levels of peroxisome proliferator-activated
receptor gamma coactivator 1α (PGC1α), the master regulator of mitochondrial biogenesis, as well as additional
genes important during mitochondrial biogenesis, cAMP
response element-binding protein (CREB) and CREBregulated transcription coactivator 1 (CRTC1). Additionally, hypoxia-inducible factor 1α (HIF1α) expression,
which has been shown to stimulate mitochondrial biogenesis following short-term hypoxia, was evaluated.
Within PAD subjects, PGC1α mRNA correlated positively with the percentage of type I fibers (r = 0.5580,
P = 0.016; Fig. 4), as would be expected in normal muscle. No correlation between PGC1α, CREB, CRTC1, nor
HIF1α expression and the percentage of fibers showing
absence of SDH staining was apparent (Additional file 6:
Figure S6). Further, expression of PGC1α, CREB, CTRC1,
and HIF1α did not correlate with any functional performance measures in PAD subjects (Table 2).
Autophagic accumulation in the center of PAD fibers

Muscle sections were co-stained with antibodies
against COX-1 and LC3 protein, the latter being an
autophagosome marker (Fig. 5). Fibers with normal
mitochondrial activity in both PAD and non-PAD subjects showed ubiquitous COX-1 staining throughout
the fiber, indicative of intermyofibrillar mitochondria,
and stronger staining around the periphery, where
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Fig. 2 Representative images of serial PAD gastrocnemius muscle sections stained for mitochondrial activity and fiber type. A succinate dehy‑
drogenase (SDH) activity; B myosin heavy chain (MyHC) composition by immunohistochemistry; C cytochrome c oxidase activity. Arrows point to
the same fiber in serial sections. Arrow, type I fiber (pink); double arrow, type IIa fiber (green); large arrowhead, type IIa/x hybrid fiber (yellow/orange).
D Correlation between the percent of total fibers with SDH cavities and type I fiber frequency in PAD subjects (n = 18, approximately 1000 fibers
counted per subject). Scale bar = 100 µm

subsarcolemmal mitochondria are localized. In normal
muscle fibers, both SDH++/COX-1 high and low muscle fibers demonstrate very little detectable LC3 staining, indicating relatively low levels of autophagy (Fig. 5,
row A). In PAD, fibers showing small central regions
with absent mitochondrial protein and activity exhibited punctate LC3 staining localized to those regions
(Fig. 5, row B). However, other PAD fibers exhibited
varying degrees of LC3 accumulation in the center
with low or absent SDH and COX-1 staining, suggesting autophagy may be increased in subjects with PAD
(Fig. 5, rows C, D). Overall, fibers that lacked COX-1
protein and SDH activity in their cores demonstrated
clear accumulation of LC3 staining (Fig. 5, row E). The
loss of the mitochondrial network in the center of fibers with LC3 accumulation can be seen more clearly
with confocal imaging, presented in Additional file 7:
Figure S7. Some fibers had relatively diffuse LC3 staining within the SDH/COX-1 cavities (Additional file 7:

Figure S7A), while the larger, more fully developed
cavities contained a dense LC3 plaque in the center
(Additional file 7: Figure S7B). To determine if the
remaining LC3 staining was due to improper fusion
of the autophagosome and the lysosome, muscle samples were co-stained with LC3 and LAMP2, a lysosome
membrane protein (Fig. 6). In non-PAD, diffuse, weak
LC3 and LAMP2 staining was visible within the fibers
(Fig. 6a). In PAD subjects, rare fibers showed overlap of
LC3 and LAMP2 (Fig. 6b), whereas the majority of fibers showed LC3 accumulation in the center of the fiber
but no clear overlap with LAMP2 (Fig. 6c).
Fiber size may affect the degree of mitochondrial
dysfunction

While capillary density did not correlate to fiber size
(r = 0.1396, P = 0.525) or the percentage of fibers showing cavities in SDH staining (r = −0.0549, P = 0.845), the
average minimum feret diameter positively correlated to
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Fig. 3 Representative images of non-PAD and PAD gastrocnemius
muscle sections stained for mitochondrial activity and mitochondrial
electron transport proteins. Top row shows succinate dehydrogenase
(SDH) activity (dark fibers are type I, intermediate fibers are type IIa,
and light fibers are type IIa/x), second row shows mitochondrial com‑
plex I, subunit 20 (orange), third row shows mitochondrial complex
IV, subunit I (COX-1; green) staining and bottom row shows complex
I and COX-1 merged. Arrows within the same column point to same
fibers. Scale bar = 50 µm

the percentage of fibers with SDH cavities (r = 0.5398,
P = 0.030; Fig. 7).

Discussion
A novel finding of this study was the correlation between
gastrocnemius muscle fiber size (minimum fiber diameter) and 4-min walking velocities in PAD subjects. While
previous reports have indicated fiber cross sectional
area decreases as much as 40 % with advancing PAD [20,
39], the current study is the first to show a positive correlation between fiber size and functional measures. In
contrast, size was not correlated to 6-min walk distance,
a measure of walking endurance. It is possible that in
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PAD patients, ischemia-related pain in the limb muscles
causes patients to stop walking during the 6-min walk
test, which may be less dependent on the muscle properties studied here.
A wide range of fiber type distributions was evident in
PAD subjects in the current study, which was not correlated to walking performance or ABI, the latter being an
accepted measure of disease severity in PAD [2, 4, 40, 41].
Although we initially hypothesized that those with the
highest proportion of type I fibers may have the highest
endurance, this was not the case, which may be due to
preferential loss of intermyofibrillar mitochondria in type
I fibers in PAD. Research has indicated there is a switch
from a type II to a type I phenotype in the gastrocnemius
muscle with advancing PAD [39]. We hypothesize that an
overall decrease in fiber size combined with an increase
in type I fiber area and concomitant mitochondrial loss
in the center of oxidative fibers may, in combination, contribute to progressive mobility loss in PAD. This hypothesis warrants further investigation.
Previous work demonstrated impaired mitochondrial
respiration and enhanced oxidative stress and damage in
the muscles of PAD subjects [10, 24, 42]. Pipinos, et al.
[10] reported reduced activity of complexes I, III, and
IV of the electron transport system in gastrocnemius
homogenates, but no difference in complex II activity.
Complex II is the only complex of the electron transport system that is fully encoded by the nuclear genome,
while the remaining 3 complexes contain mitochondrialencoded subunits [43], suggesting impairment of the
mitochondrial genome in PAD. In the current study, we
showed a disruption of both succinate dehydrogenase
(SDH, complex II) and cytochrome c oxidase (complex
IV; COX) activities in the center of fibers of PAD subjects, which is not typically seen in healthy muscle fibers.
Further, both the nuclear-encoded subunit 20 of complex
I and the mitochondrial-encoded subunit 1 of complex
IV were absent in the center of a significant number of
fibers of PAD subjects, indicating absence of intermyofibrillar mitochondrial populations in the core of the fibers. Mitochondrial absence could be due to limited O2
and nutrient delivery to the center of the fiber, as is seen
in canine models of heart failure [44]. This idea is further supported by the positive correlation between fiber
size and the percentage of fibers lacking central mitochondria in the current study. However, recent reports
have described succinate accumulation in various tissues
(heart, liver, brain, and kidney) following ischemia and
implicated the metabolite as a potential driver of reperfusion reactive oxygen species production [45]. Impaired
SDH activity and the potential accumulation of succinate
during repeated bouts of ischemia and reperfusion could
be compounding factors leading to oxidative damage and
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Fig. 4 Correlation between mRNA levels of PGC1α and type I
fiber frequency in PAD gastrocnemius muscle samples (n = 18,
approximately 1000 fibers counted per subject to quantify type I fiber
frequency)

impaired functional performance in PAD patients; these
findings require further investigation.
The maintenance of healthy cellular energetics relies on
a dynamic process of balancing the removal of damaged
or dysfunctional mitochondria through mitochondrialspecific autophagy, known as mitophagy, and mitochondrial biogenesis [46]. In the current study, PGC1α, the
master regulator of mitochondrial biogenesis, was highest in subjects with a greater percentage of oxidative
fibers, consistent with normal muscle. No correlation
between PGC1α, CREB1, CRTC1, and HIF1α expression
and the percentage of fibers with depleted central SDH
activity suggests impaired mitochondrial biogenesis was
not a major contributor to mitochondrial loss. These
data, combined with previous reports of mitochondrial
dysfunction in PAD [47], led us to hypothesize the mitochondrial cavities in the core of some fibers of PAD subjects were due to elevated mitophagy and dysfunctional
clearance of damaged mitochondria, as opposed to compromised biogenesis. One might expect an overcompensation of PCG1α to maintain mitochondrial density in
the face of elevated mitophagy. However, the autophagosome debris in fibers lacking central mitochondria may
have prevented healthy mitochondria from infiltrating
the center of the fiber. On the other hand, the lack of correlation between mitochondrial biogenesis gene expression and SDH cavities may suggest that PAD fibers are
not able to sufficiently increase mitochondrial biogenesis
to maintain oxidative capacity.
The autophagic marker, LC3, was accumulated in the
center of fibers that may be undergoing an elevated rate
of mitophagy compared to healthy fibers. A consequence
of aging is an impaired ability to degrade damaged mitochondria [48]. However, age was not associated with any
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skeletal muscle measure in our analyses. Still, there may
be a similar mechanism in PAD subjects that prevents
the proper removal of dysfunctional mitochondria. An
increase in autophagosomes in the center of fibers in
which mitochondria are actively being degraded may
imply greater mitophagy; however, the LC3 plaque evident in some fibers in which mitochondria were clearly
absent may indicate impaired fusion with the lysosome
and incomplete recycling as is evident in other diseases,
such as sporadic inclusion-body myositis [49]. This is further supported by incomplete co-localization of LC3 with
the lysosome marker, LAMP2, in PAD fibers in the current study. It is important to note that the muscle samples
collected capture a snapshot of a dynamic and ongoing
process. There may be a progression within individual
fibers of mitochondrial depolarization and death that
may or may not successfully fuse with the autophagosome and, subsequently, the lysosome to be properly
removed and recycled.
While the absence of mitochondrial activity within the
center of myofibers has been reported in diseases such
as central core disease (CCD), denervation, and hypertrophic cardiomyopathy [50], the mitochondrial disruption in the fibers of PAD appears distinct. CCD fiber
morphology presents the most similarity to our findings
but is caused by a genetic mutation in RYR1, the gene
that encodes the skeletal muscle ryanodine receptor,
disrupting calcium handling within the muscle. CCD is
often accompanied by muscle weakness, delayed motor
development, and orthopedic impairment (hip dislocation, scoliosis), and tends to present at a young age [51].
Denervation can result in a phenomenon known as “target fibers”, in which ringing of oxidative enzyme activity
occurs within the center of myofibers, but a clear threezone architecture is apparent [52], unlike the distinct cavities seen in PAD fibers. In hypertrophic cardiomyopathy,
only type I fibers are affected and present with very small
cavities at varying locations within the fiber [53], whereas
both type I and IIa fibers in PAD participants presented
with abnormal mitochondrial activity which were nearly
always centrally located. Thus, we hypothesize that the
chronic ischemic environment in PAD contributes to loss
of intermyofibrillar mitochondria unique to this disease.
Although we hypothesize that poor 4-min walking
performance in PAD is related to elevated mitophagy
and impaired clearance of damaged mitochondria, an
alternative conclusion is that mechanical capacity, rather
than bioenergetics, may be limiting normal function in
this diseased population. This is supported by our finding that myofiber size was positively correlated to 4-min
walking performance in the current study. Research has
indicated that low-impact, endurance exercise training
improves walking performance in PAD but these studies
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Fig. 5 Representative images of the variation of LC3 staining associated with cavities in SDH activity and mitochondrial COX-1 staining in PAD gas‑
trocnemius muscle sections. First column shows succinate dehydrogenase (SDH) activity (dark fibers are type I, intermediate fibers are type IIa, and
light fibers are type IIa/x), second column shows mitochondrial COX-1 protein (green), third column shows LC3 (red) and fourth column shows COX-1
and LC3 merged. Examples of normal fibers with no LC3 staining or COX-1 cavities (row A), punctate LC3 staining where a COX-1 cavitiy is forming
(row B), elevated LC3 staining with low COX-1 staining (row C), LC3 accumulation in areas lacking COX-1 staining (row D), and LC3 plaque in the
center of an SDH/COX1 cavity (COX-1; row E). Arrows within the same row point to areas of LC3 accumulation in same fiber. Scale bar = 100 µM

did not evaluate fiber size adaptations, nor the relationship between fiber size and functional performance [54].
The pathology associated with PAD is likely multifaceted,
but defects in the structure and function of the muscle, in

addition to the vasculature, must be addressed in order to
maximally improve function.
The most important limitation of this study is the relatively small sample size. Analysis of a greater number
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Fig. 6 Representative images of gastrocnemius muscle sections from non-PAD and PAD subjects stained for LC3, an autophagosome marker (red)
and LAMP2, a lysosome marker (green). A In non-PAD, very little LC3 and LAMP2 staining is apparent. In PAD, rare fibers show co-localization of
accumulated LC3 and LAMP2 (B), whereas the majority of fibers have elevated LC3 accumulation but no co-localization with LAMP2 (C). Arrows in
the same column point to the same areas of LC3 accumulation in the center of the fiber with or without LAMP2 co-localization. Scale bar = 50μm

Fig. 7 Correlation between average minimum fiber diameter and
succinate dehydrogenase (SDH) cavities in PAD gastrocnemius
samples. SDH cavities are quantified by the percentage of fibers with
cavities in SDH activity staining

of patients with PAD would confirm the association
between muscle morphology and function. Additionally, the duration of PAD was unknown in the subjects
studied, which did not allow us to quantify the exposure to ischemia and relate them to muscle characteristics. Previous study demonstrates that the exact onset
of PAD is not typically precisely identified [55]. Repeat
biopsies several months apart, as well as comparison of
the affected versus non-affected leg in PAD subjects, will
contribute to our knowledge of the pathological progression of PAD in the gastrocnemius muscle. Lastly, it was
assumed that the biopsy is representative of the entire
muscle but the authors recognize that regions of localized damage may not accurately reflect the morphology
of the entire muscle. Further, findings in one muscle may
not reflect what is happening in other lower extremity
muscles.
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Conclusions
In summary, among people with PAD, muscle fiber size
was positively correlated to 4-min walk performance,
and may be associated with the degree of mitochondrial
dysfunction evident in PAD subjects. We speculate that
the lack correlation of type I fiber frequency and function
may be due to impaired mitochondrial activity within
the center of muscle fibers, consequent to increased
mitophagy in patients with PAD. Considering the morphological features of muscle may aide in the management plan for PAD patients to improve their overall
quality of life.
Additional files
Additional file 1: Table S1. Sequence of PCR primers used for real time
quantitative PCR.
Additional file 2: Figure S2. Whisker plot of the fiber type analysis of
gastrocnemius muscle using isoform-specific myosin heavy chain (MyHC)
immunohistochemistry. The distribution of type I, type IIa, and type IIa/x
fibers is shown for non-PAD (n=7) and PAD (n=26) subjects. Approxi‑
mately 1000 fibers were analyzed per subject.
Additional file 3: Figure S3. Correlations between minimum feret diam‑
eter of gastrocnemius fibers from PAD subjects and walking performance
(n=26, approximately 1000 fibers per subject). A) type I fiber minimum
feret diameter versus normal-paced 4-m walking velocity; B) type I fiber
minimum feret diameter versus fastest-paced 4-m walking velocity; C)
average fiber minimum feret diameter versus normal-paced 4-m walking
velocity; and D) average fiber minimum feret diameter versus fastestpaced 4-m walking velocity.
Additional file 4: Figure S4. Lectin staining to quantify capillary density.
Representative images of lectin binding to endothelial cells in non-PAD
(A) and PAD (B) gastrocnemius muscle sections. C) Quantification of lectin
staining, expressed as lectin+ capillaries/fiber in PAD (n=18) compared to
non-PAD (n=7) participants (ANOVA, P=0.082). Approximately 600 fibers
were analyzed per subject. Data represented as Mean ± SEM. Scale bar =
50 µm.
Additional file 5: Figure S5. Representative images of oil red O (ORO, A)
and succinate dehydrogenase activity (SDH, B) staining of gastrocnemius
serial sections. Excessive lipid does not accumulate in the SDH cavities.
Arrows point to same fibers. Scale bar = 100 µM.
Additional file 6: Figure S6. Correlations between the percentage of
fibers with cavities in SDH staining in PAD gastrocnemius muscle sections
(n=18, approximately 1000 fibers analyzed per subject) and PGC1α (A),
CREB (B), CRTC1 (C), and HIF1α (D) mRNA expression.
Additional file 7: Figure S7. Representative confocal images of PAD
gastrocnemius muscle sections. A) LC3 (red) is diffuse throughout cavity
where mitochondrial cytochrome c oxidase protein (complex IV; COX-1;
green) is absent. B) LC3 has formed a plaque in the center of the COX-1
protein cavity. Scale bar = 10 µM.
Abbreviations
ABI: ankle brachial index; CCD: central core disease; COX: cytochrome c oxi‑
dase; CREB: cAMP response element-binding protein 1; CRTC1: CREB-regulated
transcription coactivator 1; HIF1α: hypoxia-inducible factor 1α; LAMP2: lyso‑
somal associated membrane protein 2; LC3: microtubule-associated protein
light chain 3; MyHC: myosin heavy chain; ORO: oil red O; PAD: peripheral artery
disease; PGC1α: peroxisome proliferator-activated receptor gamma coactiva‑
tor 1α; RYR1: ryanodine receptor 1; SDH: succinate dehydrogenase.

Page 13 of 15

Authors’ contributions
CAP, MMM, RLS, LF, MGF, MRK, CL, and MC designed the observational study.
MMM recruited participants and was responsible for the original clinical trials
and oversight of functional testing. RLS performed muscle biopsies and col‑
lected tissue samples. CAP was responsible for oversight and interpretation of all
muscle tissue analyses. SHW and CAP wrote the manuscript; SHW and KK gener‑
ated figures and assisted with statistical analyses of muscle measures. SHW,
KK, AWB and MGF performed muscle tissue analyses. LT, LZ and YG performed
statistical analyses. All authors approved the final version of the manuscript.
Author details
1
College of Health Sciences and Center for Muscle Biology, University
of Kentucky, 900 S Limestone CTW105, Lexington, KY 40536, USA. 2 Division
of General Internal Medicine, Department of Medicine, Northwestern Uni‑
versity Feinberg School of Medicine, 750 North Lake Shore Drive, 10th Floor,
Chicago 60611, USA. 3 Department of Preventive Medicine, Northwestern Uni‑
versity Feinberg School of Medicine, Chicago, IL, USA. 4 Department of Neurol‑
ogy, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
5
National Institute on Aging, Baltimore, MD, USA. 6 Department of Health
Research & Policy, Stanford University, Stanford, CA, USA. 7 Department of Sur‑
gery, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
8
Jesse Brown Veterans Affairs Medical Center, Chicago, IL, USA. 9 Department
of Family Medicine and Public Health, University of California at San Diego,
La Jolla, CA, USA. 10 Department of Aging and Geriatric Research, University
of Florida Institute on Aging, Gainesville, FL, USA.
Acknowledgements
The authors thank Ms. Jyothi Mula for immunohistochemical protocol devel‑
opment and technical assistance. Additionally, Ms. Jacquelyn Brown assisted
with sample analysis.
Competing interests
The authors declare that they have no competing interests.
Ethics approval and consent to participate
All studies were approved by the Northwestern University Institutional Review
Board.
Disclosures
All authors have declared no conflicts of interest regarding this manuscript.
Sources of funding
The work was supported by NIH Grants R01HL088589, R01HL083064,
R01HL089619, R01HL107510, R21-AG047510, and R01HL109244 (M.M.M.) and
R01AR60701-S1 (C.A.P.).
Received: 25 May 2016 Accepted: 6 September 2016

References
1. McDermott MM, Greenland P, Liu K, Guralnik JM, Criqui MH, Dolan NC,
Chan C, Celic L, Pearce WH, Schneider JR, et al. Leg symptoms in periph‑
eral arterial disease: associated clinical characteristics and functional
impairment. JAMA. 2001;286:1599–606.
2. McDermott MM, Greenland P, Liu K, Guralnik JM, Celic L, Criqui MH, Chan
C, Martin GJ, Schneider J, Pearce WH, et al. The ankle brachial index is
associated with leg function and physical activity: the walking and leg
circulation study. Ann Intern Med. 2002;136:873–83.
3. McDermott MM, Liu K, Greenland P, Guralnik JM, Criqui MH, Chan C,
Pearce WH, Schneider JR, Ferrucci L, Celic L, et al. Functional decline in
peripheral arterial disease: associations with the ankle brachial index and
leg symptoms. JAMA. 2004;292:453–61.
4. McDermott MM, Guralnik JM, Tian L, Liu K, Ferrucci L, Liao Y, Sharma
L, Criqui MH. Associations of borderline and low normal anklebrachial index values with functional decline at 5-year follow-up:
the WALCS (walking and leg circulation study). J Am Coll Cardiol.
2009;53:1056–62.

White et al. J Transl Med (2016) 14:284

5.
6.

7.
8.
9.
10.

11.

12.
13.

14.

15.

16.

17.
18.
19.
20.
21.

22.
23.
24.

McDermott MM, Guralnik JM, Tian L, Ferrucci L, Liu K, Liao Y, Criqui MH.
Baseline functional performance predicts the rate of mobility loss in per‑
sons with peripheral arterial disease. J Am Coll Cardiol. 2007;50:974–82.
McDermott MM, Fried L, Simonsick E, Ling S, Guralnik JM. Asymptomatic
peripheral arterial disease is independently associated with impaired
lower extremity functioning: the women’s health and aging study. Circu‑
lation. 2000;101:1007–12.
Gardner AW, Montgomery PS, Killewich LA. Natural history of physi‑
cal function in older men with intermittent claudication. J Vasc Surg.
2004;40:73–8.
Murray CJ, Atkinson C, Bhalla K, Birbeck G, Burstein R, Chou D, Dellavalle
R, Danaei G, Ezzati M, Fahimi A, et al. The state of US health, 1990–2010:
burden of diseases, injuries, and risk factors. JAMA. 2013;310:591–608.
Gillani S, Cao J, Suzuki T, Hak DJ. The effect of ischemia reperfusion injury
on skeletal muscle. Injury. 2012;43:670–5.
Pipinos II, Judge AR, Zhu Z, Selsby JT, Swanson SA, Johanning JM, Baxter
BT, Lynch TG, Dodd SL. Mitochondrial defects and oxidative dam‑
age in patients with peripheral arterial disease. Free Radic Biol Med.
2006;41:262–9.
Pipinos II, Sharov VG, Shepard AD, Anagnostopoulos PV, Katsamouris
A, Todor A, Filis KA, Sabbah HN. Abnormal mitochondrial respiration in
skeletal muscle in patients with peripheral arterial disease. J Vasc Surg.
2003;38:827–32.
Vignaud A, Hourde C, Medja F, Agbulut O, Butler-Browne G, Ferry A.
Impaired skeletal muscle repair after ischemia-reperfusion injury in mice.
J Biomed Biotechnol. 2010;2010:724914.
Puntel GO, Carvalho NR, Dobrachinski F, Salgueiro AC, Puntel RL, Folmer
V, Barbosa NB, Royes LF, Rocha JB, Soares FA. Cryotherapy reduces
skeletal muscle damage after ischemia/reperfusion in rats. J Anat.
2013;222:223–30.
Anderson JD, Epstein FH, Meyer CH, Hagspiel KD, Wang H, Berr SS,
Harthun NL, Weltman A, Dimaria JM, West AM, Kramer CM. Multifacto‑
rial determinants of functional capacity in peripheral arterial disease:
uncoupling of calf muscle perfusion and metabolism. J Am Coll Cardiol.
2009;54:628–35.
Lee CG, Boyko EJ, Strotmeyer ES, Lewis CE, Cawthon PM, Hoffman AR,
Everson-Rose SA, Barrett-Connor E, Orwoll ES. Osteoporotic fractures in
men study research g: association between insulin resistance and lean
mass loss and fat mass gain in older men without diabetes mellitus. J Am
Geriatr Soc. 2011;59:1217–24.
Thompson JR, Swanson SA, Haynatzki G, Koutakis P, Johanning JM,
Reppert PR, Papoutsi E, Miserlis D, Zhu Z, Casale GP, Pipinos II. Protein
concentration and mitochondrial content in the gastrocnemius predicts
mortality rates in patients with peripheral arterial disease. Ann Surg.
2015;261:605–10.
Regensteiner JG, Hargarten ME, Rutherford RB, Hiatt WR. Functional ben‑
efits of peripheral vascular bypass surgery for patients with intermittent
claudication. Angiology. 1993;44:1–10.
Nehler MR, McDermott MM, Treat-Jacobson D, Chetter I, Regensteiner
JG. Functional outcomes and quality of life in peripheral arterial disease:
current status. Vasc Med. 2003;8:115–26.
Picard M, Hepple RT, Burelle Y. Mitochondrial functional specialization in
glycolytic and oxidative muscle fibers: tailoring the organelle for optimal
function. Am J Physiol Cell Physiol. 2012;302:C629–41.
McGuigan MR, Bronks R, Newton RU, Sharman MJ, Graham JC, Cody DV,
Kraemer WJ. Muscle fiber characteristics in patients with peripheral arte‑
rial disease. Med Sci Sports Exerc. 2001;33:2016–21.
Steinacker JM, Opitz-Gress A, Baur S, Lormes W, Bolkart K, Sunder-Plass‑
mann L, Liewald F, Lehmann M, Liu Y. Expression of myosin heavy chain
isoforms in skeletal muscle of patients with peripheral arterial occlusive
disease. J Vasc Surg. 2000;31:443–9.
Regensteiner JG, Wolfel EE, Brass EP, Carry MR, Ringel SP, Hargarten ME,
Stamm ER, Hiatt WR. Chronic changes in skeletal muscle histology and
function in peripheral arterial disease. Circulation. 1993;87:413–21.
Clyne CA, Weller RO, Bradley WG, Silber DI, O’Donnell TF Jr, Callow AD.
Ultrastructural and capillary adaptation of gastrocnemius muscle to
occlusive peripheral vascular disease. Surgery. 1982;92:434–40.
Pipinos II, Judge AR, Selsby JT, Zhu Z, Swanson SA, Nella AA, Dodd SL.
The myopathy of peripheral arterial occlusive disease: part 2. Oxidative
stress, neuropathy, and shift in muscle fiber type. Vasc Endovascular Surg.
2008;42:101–12.

Page 14 of 15

25. McDermott MM, Liu K, Carr J, Criqui MH, Tian L, Li D, Ferrucci L, Guralnik
JM, Kramer CM, Yuan C, et al. Superficial femoral artery plaque, the
ankle-brachial index, and leg symptoms in peripheral arterial disease: the
walking and leg circulation study (WALCS) III. Circ Cardiovasc Imaging.
2011;4:246–52.
26. McDermott MM, Greenland P, Liu K, Tian L, Green D, Shah SJ, Huff‑
man M, Wilkins J, Kibbe M, Liao Y, et al. Vulnerable blood in high risk
vascular patients: study design and methods. Contemp Clin Trials.
2014;38:121–9.
27. McDermott MM, Liu K, Green D, Greenland P, Tian L, Kibbe M, Tracy R,
Shah S, Wilkins JT, Huffman M, et al. Changes in D-dimer and inflamma‑
tory biomarkers before ischemic events in patients with peripheral artery
disease: the BRAVO study. Vasc Med. 2016;21:12–20.
28. McDermott MM, Liu K, Guralnik JM, Criqui MH, Spring B, Tian L, Doman‑
chuk K, Ferrucci L, Lloyd-Jones D, Kibbe M, et al. Home-based walking
exercise intervention in peripheral artery disease: a randomized clinical
trial. JAMA. 2013;310:57–65.
29. McDermott MM, Domanchuk K, Liu K, Guralnik JM, Tian L, Criqui MH,
Ferrucci L, Kibbe M, Jones DL, Pearce W, et al. The group oriented arterial
leg study (GOALS) to improve walking performance in patients with
peripheral artery disease. Contemp Clin Trials. 2012;33:1311–20.
30. Domanchuk K, Ferrucci L, Guralnik JM, Criqui MH, Tian L, Liu K, Losordo
D, Stein J, Green D, Kibbe M, et al. Progenitor cell release plus exercise to
improve functional performance in peripheral artery disease: the PROPEL
study. Contemp Clin Trials. 2013;36:502–9.
31. Criqui MH, Denenberg JO, Bird CE, Fronek A, Klauber MR, Langer RD. The
correlation between symptoms and non-invasive test results in patients
referred for peripheral arterial disease testing. Vasc Med. 1996;1:65–71.
32. McDermott MM, Criqui MH, Liu K, Guralnik JM, Greenland P, Martin
GJ, Pearce W. Lower ankle/brachial index, as calculated by averaging
the dorsalis pedis and posterior tibial arterial pressures, and associa‑
tion with leg functioning in peripheral arterial disease. J Vasc Surg.
2000;32:1164–71.
33. Shadman R, Criqui MH, Bundens WP, Fronek A, Denenberg JO, Gamst
AC, McDermott MM. Subclavian artery stenosis: prevalence, risk fac‑
tors, and association with cardiovascular diseases. J Am Coll Cardiol.
2004;44:618–23.
34. McDermott MM, Tian L, Liu K, Guralnik JM, Ferrucci L, Tan J, Pearce WH,
Schneider JR, Criqui MH. Prognostic value of functional performance for
mortality in patients with peripheral artery disease. J Am Coll Cardiol.
2008;51:1482–9.
35. Guralnik JM, Ferrucci L, Simonsick EM, Salive ME, Wallace RB. Lowerextremity function in persons over the age of 70 years as a predictor of
subsequent disability. N Engl J Med. 1995;332:556–61.
36. Guralnik JM, Ferrucci L, Pieper CF, Leveille SG, Markides KS, Ostir GV,
Studenski S, Berkman LF, Wallace RB. Lower extremity function and
subsequent disability: consistency across studies, predictive models, and
value of gait speed alone compared with the short physical performance
battery. J Gerontol A Biol Sci Med Sci. 2000;55:M221–31.
37. Kirkeby S, Mandel U, Vedtofte P. Identification of capillaries in sections
from skeletal muscle by use of lectins and monoclonal antibodies react‑
ing with histo-blood group ABH antigens. Glycoconj J. 1993;10:181–8.
38. Parsons D, McIntyre K, Schulz W, Stray-Gundersen J. Capillarity of elite
cross-country skiers: a lectin (Ulex europaeus I) marker. Scand J Med Sci
Sports. 1993;3:207–16.
39. Koutakis P, Weiss DJ, Miserlis D, Shostrom VK, Papoutsi E, Ha DM, Car‑
penter LA, McComb RD, Casale GP, Pipinos II. Oxidative damage in the
gastrocnemius of patients with peripheral artery disease is myofiber type
selective. Redox Biol. 2014;2:921–8.
40. Ankle Brachial Index C, Fowkes FG, Murray GD, Butcher I, Heald CL, Lee
RJ, Chambless LE, Folsom AR, Hirsch AT, Dramaix M, et al. Ankle brachial
index combined with Framingham Risk Score to predict cardiovascular
events and mortality: a meta-analysis. JAMA. 2008;300:197–208.
41. Aboyans V, Criqui MH, Abraham P, Allison MA, Creager MA, Diehm C,
Fowkes FG, Hiatt WR, Jonsson B, Lacroix P, et al. Measurement and
interpretation of the ankle-brachial index: a scientific statement from the
American Heart Association. Circulation. 2012;126:2890–909.
42. Weiss DJ, Casale GP, Koutakis P, Nella AA, Swanson SA, Zhu Z, Miserlis D,
Johanning JM, Pipinos II. Oxidative damage and myofiber degeneration
in the gastrocnemius of patients with peripheral arterial disease. J Transl
Med. 2013;11:230.

White et al. J Transl Med (2016) 14:284

43. Wanagat J, Cao Z, Pathare P, Aiken JM. Mitochondrial DNA deletion muta‑
tions colocalize with segmental electron transport system abnormalities,
muscle fiber atrophy, fiber splitting, and oxidative damage in sarcopenia.
FASEB J. 2001;15:322–32.
44. Rosca MG, Hoppel CL. Mitochondrial dysfunction in heart failure. Heart
Fail Rev. 2013;18:607–22.
45. Chouchani ET, Pell VR, Gaude E, Aksentijevic D, Sundier SY, Robb EL,
Logan A, Nadtochiy SM, Ord EN, Smith AC, et al. Ischaemic accumula‑
tion of succinate controls reperfusion injury through mitochondrial ROS.
Nature. 2014;515:431–5.
46. Kim I, Rodriguez-Enriquez S, Lemasters JJ. Selective degradation of mito‑
chondria by mitophagy. Arch Biochem Biophys. 2007;462:245–53.
47. Koutakis P, Miserlis D, Myers SA, Kim JK, Zhu Z, Papoutsi E, Swanson SA,
Haynatzki G, Ha DM, Carpenter LA, et al. Abnormal accumulation of
desmin in gastrocnemius myofibers of patients with peripheral artery
disease: associations with altered myofiber morphology and density,
mitochondrial dysfunction and impaired limb function. J Histochem
Cytochem. 2015;63:256–69.
48. Rygiel KA, Picard M, Turnbull DM. The ageing neuromuscular sys‑
tem and sarcopenia—a mitochondrial perspective. J Physiol.
2016;594(16):4499–512.

Page 15 of 15

49. Nogalska A, D’Agostino C, Terracciano C, Engel WK, Askanas V. Impaired
autophagy in sporadic inclusion-body myositis and in endoplasmic
reticulum stress-provoked cultured human muscle fibers. Am J Pathol.
2010;177:1377–87.
50. Jungbluth H. Central core disease. Orphanet J Rare Dis. 2007;2:25.
51. Malicdan MCV, Nishino I. Central core disease. In: Pagon RA, Adam MP,
Ardinger HH, Wallace SE, Amemiya A, Bean LJH, Bird TD, Fong CT, Mefford
HC, Smith RJH, Stephens K, editors. GeneReviews(R). Seattle (WA): Univer‑
sity of Washington; 1993.
52. Mrak RE, Saito A, Evans OB, Fleischer S. Autophagic degradation in human
skeletal muscle target fibers. Muscle Nerve. 1982;5:745–53.
53. Caforio AL, Rossi B, Risaliti R, Siciliano G, Marchetti A, Angelini C, Crea F,
Mariani M, Muratorio A. Type 1 fiber abnormalities in skeletal muscle of
patients with hypertrophic and dilated cardiomyopathy: evidence of
subclinical myogenic myopathy. J Am Coll Cardiol. 1989;14:1464–73.
54. Haas TL, Lloyd PG, Yang HT, Terjung RL. Exercise training and peripheral
arterial disease. Compr Physiol. 2012;2:2933–3017.
55. Hirsch AT, Criqui MH, Treat-Jacobson D, Regensteiner JG, Creager MA, Olin
JW, Krook SH, Hunninghake DB, Comerota AJ, Walsh ME, et al. Peripheral
arterial disease detection, awareness, and treatment in primary care.
JAMA. 2001;286:1317–24.

Submit your next manuscript to BioMed Central
and we will help you at every step:
• We accept pre-submission inquiries
• Our selector tool helps you to find the most relevant journal
• We provide round the clock customer support
• Convenient online submission
• Thorough peer review
• Inclusion in PubMed and all major indexing services
• Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit

